Delenex Therapeutics AG
Delenex Therapeutics is a Zurich, Switzerland-based, privately held, new clinical stage biotechnology company focusing in research and development of its antibody fragments for Delivering next generation Therapeutics application. Delenex uses ESBATech’s proprietary screening platform IMMUNA and ESBATech’s fully human antibody frameworks against targets of relevance currently in two franchises: rheumatology and respiratory, advancing a pipeline of novel single-chain antibody fragments for topical and/or local delivery, to ensure safe and convenient patient therapy.
